Cancers 2011, 3(2), 2667-2678; doi:10.3390/cancers3022667
Review

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer

1 Department of Internal Medicine, National Yang-Ming University Hospital, Yilan 260, Taiwan 2 Department of Chest Medicine, Far Eastern Memorial Hospital, Taipei 220, Taiwan 3 Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei 100, Taiwan
* Author to whom correspondence should be addressed.
Received: 28 April 2011; in revised form: 1 June 2011 / Accepted: 7 June 2011 / Published: 10 June 2011
(This article belongs to the Special Issue Lung Cancer)
PDF Full-text Download PDF Full-Text [198 KB, uploaded 10 June 2011 09:51 CEST]
Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) cases comprise approximately 85% of the lung cancer cases. Before the era of target therapy, platinum-based doublet chemotherapy only led to a median survival of 8–9 months and a one-year survival of 30%–40% in patients with advanced NSCLC. In July 2002, gefitinib, a small-molecule epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), was approved for the treatment of patients with advanced NSCLC in Japan. After the widespread use of gefitinib in the treatment of NSCLC, there have been many new studies regarding the association between the clinical anticancer efficacy of gefitinib and the somatic EGFR mutation status in patients with NSCLC. This article summarizes the role of EGFR mutations in lung cancer and the use of EGFR antagonists in the treatment of lung cancer and its associated adverse effects.
Keywords: epidermal growth factor receptor; tyrosine kinase inhibitors; gefitinib; erlotinib

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Chang, S.-C.; Chang, C.-Y.; Shih, J.-Y. The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer. Cancers 2011, 3, 2667-2678.

AMA Style

Chang S-C, Chang C-Y, Shih J-Y. The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer. Cancers. 2011; 3(2):2667-2678.

Chicago/Turabian Style

Chang, Shih-Chieh; Chang, Cheng-Yu; Shih, Jin-Yuan. 2011. "The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer." Cancers 3, no. 2: 2667-2678.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert